Should CRISPR be banned for use? In a piece from the Innovative Genomics Institute titled “CRISPR Ethics,” the institute outlines the major ethical questions surrounding CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology. The article explains that CRISPR allows scientists to precisely modify DNA and holds great promise for treating genetic diseases. At the same time, it raises concerns about human germline editing, the possibility of “designer babies,” and the need for strong global oversight. At its core, CRISPR is a chemical system: the Cas9 enzyme catalyzes the hydrolysis of phosphodiester bonds in DNA, allowing scientists to break and reform covalent bonds in the genome. China is mentioned in the context of a major ethical controversy: it describes how, in November 2018, a Chinese scientist, He Jiankui, announced the birth of twin girls whose embryos he had edited with CRISPR (editing the CCR5 gene to purportedly protect them from HIV infection). This action sparked international outcry and condemnation because it violated widely-accepted ethical norms and lacked proper oversight, and He was later sentenced to three years in prison — an event that highlighted the need for clear guidelines and oversight on human embryo editing.
From a chemistry perspective, CRISPR operates at the molecular level. The Cas9 enzyme cuts DNA by breaking specific chemical bonds in the DNA backbone, relying on principles such as molecular structure, bonding interactions, and enzyme catalysis. The specificity of CRISPR depends on chemical base-pairing interactions between guide RNA and DNA, which are governed by hydrogen bonding and molecular geometry. The effectiveness and safety of CRISPR-based therapies also depend on chemically designed delivery systems that transport gene-editing components into cells. Although often categorized as biology, CRISPR is fundamentally applied molecular chemistry in living systems.
The article places the controversy in a broader social and regulatory context rather than presenting CRISPR as inherently dangerous. It distinguishes between therapeutic uses, such as correcting serious genetic disorders, and enhancement applications that raise deeper ethical concerns. In doing so, it avoids reinforcing chemophobia. Scientists are portrayed not as reckless experimenters, but as actively engaged in ethical reflection and global governance discussions.
CRISPR-based therapies are advancing within established regulatory frameworks—particularly through the requirements of the U.S. Food and Drug Administration and other global regulators, with early-stage trials (Phase I) focused on safety and dosing and later stages (Phases II and III) designed to generate the efficacy data needed for formal approval. It notes the historic first approval of a CRISPR-based medicine (Casgevy) for sickle cell disease and beta thalassemia, and discusses how financing and reimbursement arrangements (e.g., with state Medicaid programs and the UK’s NHS) are evolving as part of translating these approvals into real-world treatment access. The article also emphasizes that the first personalized CRISPR therapy, developed and delivered in six months, sets an important precedent for rapid regulatory pathways for “platform therapies” in the U.S., potentially shaping how future bespoke and on-demand gene-editing treatments are evaluated and cleared by regulators.
Overall, the article connects chemical principles to real-world medical innovation while also encouraging critical thinking about regulation, risk, and societal responsibility. Rather than promoting fear, it presents CRISPR as a powerful chemical technology that requires careful and informed oversight.
https://innovativegenomics.org/crisprpedia/crispr-ethics/#Introduction
https://innovativegenomics.org/news/crispr-clinical-trials-2025/
I like your title. It certainly raises the relevant questions. The report you refer to comes from a research group working on genetic engineering methods. Generally this kind of report is something that general media would consider as a source. The Livescience source where you got your graphic is more of a critical journalistic source that talks to scientists and tries to independently evaluate the significance of the research to the public and interpret it to the public. That said the IGI report is interesting and does give a good account of the issues associated with using CRISPR on people. Your summaries are clear and well organized. The figure is quit helpful in explaining how CRISPR works. I think it would be comprehensible to a general reader. I tend to agree with your evaluation that the report makes a pretty good well-supported case that there is a place for responsibly used CRISPR in human therapeutics. You led us in a pretty good discussion I thought. Overall, very solid.
ReplyDelete